InspireMD, Inc. Series B Warrants
NSPRZ
NSPRZ was delisted on the 14th of March, 2022.
4 hedge funds and large institutions have $18K invested in InspireMD, Inc. Series B Warrants in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
81% less capital invested
Capital invested by funds: $97K → $18K (-$79K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$85K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.18K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.12K |
| 5 |
VF
Virtu Financial
New York
|
-$634 |
NSPRZ Hedge Fund Activity: Q1 2021 in Review
4 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in InspireMD, Inc. Series B Warrants (NSPRZ) for Q1 2021, worth a combined $18K — down 81% from $97K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NSPRZ and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 0 added.
The largest seller was Anson Funds Management, exiting entirely with an estimated $85K sold.
- 4 institutional investors held InspireMD, Inc. Series B Warrants (NSPRZ) as of Q1 2021, down from 5 in Q4 2020.
- Funds reported $18K of InspireMD, Inc. Series B Warrants stock for Q1 2021, down 81% quarter-over-quarter.
- 0 funds opened new InspireMD, Inc. Series B Warrants positions in Q1 2021 and 1 closed out, a net change of -1 holder.
- The largest InspireMD, Inc. Series B Warrants seller in Q1 2021 was Anson Funds Management, an estimated $85K sold.
Based on aggregated 13F filings for Q1 2021.